Wednesday, February 23, 2011

Noven files Hatch-Waxman case against Mylan related to Vivelle-Dot

Noven, located in Miami and a subsidiary of Hisamitsu Pharmaceutical Co. , has filed a Hatch-Waxman suit against Mylan related to Mylan's proposed generic equivalent of Vivelle-Dot, a transdermal patch used to treat the symptoms associated with menopause.

Back in the day, victorious Pittsburgh Pirates from the World Series of 1960 invested in Mylan. But for a rock on the infield of Forbes Field, who knows?

UPDATE on 27 Feb 2011:

The 10 Biggest-Selling Drugs That Are About to Lose Their Patent
with discussion of Lipitor:

Cholesterol fighter Lipitor held the title "best-selling drug" for a few years, and has been a major source of income for the world's biggest drug company, Pfizer (PFE). Lipitor (atorvastatin) was released in 1998, and by 2006 it had reached peak sales of $12.9 billion, accounting for 27% of the company's revenue. In 2010, with $10.8 billion in sales, Lipitor still accounted for 15.8% of total revenue, even with the addition of Wyeth's operations.


Post a Comment

<< Home